Yes, it's in the Feb 20 PR:

BASED ON STRONG RESULTS IN ITS PRE-CLINICAL ANIMAL STUDY, CYTODYN FILES FOR ORPHAN DRUG DESIGNATION FOR TRIPLE-NEGATIVE BREAST CANCER